Anna Musket
Overview
Explore the profile of Anna Musket including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
39
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Musket A, Davern S, Elam B, Musich P, Moorman J, Jiang Y
Front Nucl Med
. 2024 Oct;
3:1323514.
PMID: 39355029
Radionuclide-mediated diagnosis and therapy have emerged as effective and low-risk approaches to treating breast cancer. Compared to traditional anatomic imaging techniques, diagnostic radionuclide-based molecular imaging systems exhibit much greater sensitivity...
2.
Musket A, Moorman J, Zhang J, Jiang Y
Int J Mol Sci
. 2024 May;
25(9).
PMID: 38731883
The serine-threonine kinase protein kinase A (PKA) is a cyclic AMP (cAMP)-dependent intracellular protein with multiple roles in cellular biology including metabolic and transcription regulation functions. The cAMP-dependent protein kinase...
3.
Qin A, Qin Y, Lee J, Musket A, Ying M, Krenciute G, et al.
J Transl Med
. 2023 Oct;
21(1):682.
PMID: 37779207
Background: Recent progress in cancer immunotherapy encourages the expansion of chimeric antigen receptor (CAR) T cell therapy in solid tumors including hepatocellular carcinoma (HCC). Overexpression of MET receptor tyrosine kinase...
4.
Qin A, Musket A, Musich P, Schweitzer J, Xie Q
Neurooncol Adv
. 2021 Nov;
3(1):vdab133.
PMID: 34806012
Glioblastoma (GBM) is the most malignant primary brain tumor without effective therapies. Since bevacizumab was FDA approved for targeting vascular endothelial growth factor receptor 2 (VEGFR2) in adult patients with...
5.
Qin Y, Musket A, Kou J, Preiszner J, Tschida B, Qin A, et al.
Neurooncol Adv
. 2020 Jul;
2(1):vdaa067.
PMID: 32642717
Background: Aberrant MET receptor tyrosine kinase (RTK) activation leads to invasive tumor growth in different types of cancer. Overexpression of MET and its ligand hepatocyte growth factor (HGF) occurs more...